The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: The L.I.F.T. study

Claus Roehrborn, Steven N. Gange, Neal D. Shore, Jonathan L. Giddens, Damien M. Bolton, Barrett E. Cowan, B. Thomas Brown, Kevin T. McVary, Alexis E. Te, Shahram S. Gholami, Prem Rashid, William G. Moseley, Peter T. Chin, William T. Dowling, Sheldon J. Freedman, Peter F. Incze, K. Scott Coffield, Fernando D. Borges, Daniel B. Rukstalis

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Purpose: We report the first multicenter randomized blinded trial of the prostatic urethral lift for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Materials and Methods: Men at least 50 years old with AUASI (American Urological Association Symptom Index) 13 or greater, a maximum flow rate 12 ml per second or less and a prostate 30 to 80 cc were randomized 2:1 between prostatic urethral lift and sham. In the prostatic urethral lift group small permanent implants are placed within the prostate to retract encroaching lobes and open the prostatic urethra. Sham entailed rigid cystoscopy with sounds mimicking the prostatic urethral lift. The primary end point was comparison of AUASI reduction at 3 months. The prostatic urethral lift arm subjects were followed to 1 year and assessed for lower urinary tract symptoms, peak urinary flow rate, quality of life and sexual function. Results: A total of 206 men were randomized (prostatic urethral lift 140 vs sham 66). The prostatic urethral lift and sham AUASI was reduced by 11.1 ± 7.67 and 5.9 ± 7.66, respectively (p = 0.003), thus meeting the primary end point. Prostatic urethral lift subjects experienced AUASI reduction from 22.1 baseline to 18.0, 11.0 and 11.1 at 2 weeks, 3 months and 12 months, respectively, p <0.001. Peak urinary flow rate increased 4.4 ml per second at 3 months and was sustained at 4.0 ml per second at 12 months, p <0.001. Adverse events were typically mild and transient. There was no occurrence of de novo ejaculatory or erectile dysfunction. Conclusions: The prostatic urethral lift, reliably performed with the patient under local anesthesia, provides rapid and sustained improvement in symptoms and flow, while preserving sexual function.

Original languageEnglish (US)
Pages (from-to)2161-2167
Number of pages7
JournalJournal of Urology
Volume190
Issue number6
DOIs
StatePublished - Dec 2013

Fingerprint

Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Prostate
Cystoscopy
Erectile Dysfunction
Urethra
Local Anesthesia
Quality of Life
Therapeutics

Keywords

  • Prostate
  • Prostatic hyperplasia
  • Surgical procedures, minimally invasive
  • Therapeutics
  • Urethra

ASJC Scopus subject areas

  • Urology

Cite this

The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia : The L.I.F.T. study. / Roehrborn, Claus; Gange, Steven N.; Shore, Neal D.; Giddens, Jonathan L.; Bolton, Damien M.; Cowan, Barrett E.; Thomas Brown, B.; McVary, Kevin T.; Te, Alexis E.; Gholami, Shahram S.; Rashid, Prem; Moseley, William G.; Chin, Peter T.; Dowling, William T.; Freedman, Sheldon J.; Incze, Peter F.; Scott Coffield, K.; Borges, Fernando D.; Rukstalis, Daniel B.

In: Journal of Urology, Vol. 190, No. 6, 12.2013, p. 2161-2167.

Research output: Contribution to journalArticle

Roehrborn, C, Gange, SN, Shore, ND, Giddens, JL, Bolton, DM, Cowan, BE, Thomas Brown, B, McVary, KT, Te, AE, Gholami, SS, Rashid, P, Moseley, WG, Chin, PT, Dowling, WT, Freedman, SJ, Incze, PF, Scott Coffield, K, Borges, FD & Rukstalis, DB 2013, 'The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: The L.I.F.T. study', Journal of Urology, vol. 190, no. 6, pp. 2161-2167. https://doi.org/10.1016/j.juro.2013.05.116
Roehrborn, Claus ; Gange, Steven N. ; Shore, Neal D. ; Giddens, Jonathan L. ; Bolton, Damien M. ; Cowan, Barrett E. ; Thomas Brown, B. ; McVary, Kevin T. ; Te, Alexis E. ; Gholami, Shahram S. ; Rashid, Prem ; Moseley, William G. ; Chin, Peter T. ; Dowling, William T. ; Freedman, Sheldon J. ; Incze, Peter F. ; Scott Coffield, K. ; Borges, Fernando D. ; Rukstalis, Daniel B. / The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia : The L.I.F.T. study. In: Journal of Urology. 2013 ; Vol. 190, No. 6. pp. 2161-2167.
@article{ff9c87660cc048bd907f93e76da2a329,
title = "The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: The L.I.F.T. study",
abstract = "Purpose: We report the first multicenter randomized blinded trial of the prostatic urethral lift for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Materials and Methods: Men at least 50 years old with AUASI (American Urological Association Symptom Index) 13 or greater, a maximum flow rate 12 ml per second or less and a prostate 30 to 80 cc were randomized 2:1 between prostatic urethral lift and sham. In the prostatic urethral lift group small permanent implants are placed within the prostate to retract encroaching lobes and open the prostatic urethra. Sham entailed rigid cystoscopy with sounds mimicking the prostatic urethral lift. The primary end point was comparison of AUASI reduction at 3 months. The prostatic urethral lift arm subjects were followed to 1 year and assessed for lower urinary tract symptoms, peak urinary flow rate, quality of life and sexual function. Results: A total of 206 men were randomized (prostatic urethral lift 140 vs sham 66). The prostatic urethral lift and sham AUASI was reduced by 11.1 ± 7.67 and 5.9 ± 7.66, respectively (p = 0.003), thus meeting the primary end point. Prostatic urethral lift subjects experienced AUASI reduction from 22.1 baseline to 18.0, 11.0 and 11.1 at 2 weeks, 3 months and 12 months, respectively, p <0.001. Peak urinary flow rate increased 4.4 ml per second at 3 months and was sustained at 4.0 ml per second at 12 months, p <0.001. Adverse events were typically mild and transient. There was no occurrence of de novo ejaculatory or erectile dysfunction. Conclusions: The prostatic urethral lift, reliably performed with the patient under local anesthesia, provides rapid and sustained improvement in symptoms and flow, while preserving sexual function.",
keywords = "Prostate, Prostatic hyperplasia, Surgical procedures, minimally invasive, Therapeutics, Urethra",
author = "Claus Roehrborn and Gange, {Steven N.} and Shore, {Neal D.} and Giddens, {Jonathan L.} and Bolton, {Damien M.} and Cowan, {Barrett E.} and {Thomas Brown}, B. and McVary, {Kevin T.} and Te, {Alexis E.} and Gholami, {Shahram S.} and Prem Rashid and Moseley, {William G.} and Chin, {Peter T.} and Dowling, {William T.} and Freedman, {Sheldon J.} and Incze, {Peter F.} and {Scott Coffield}, K. and Borges, {Fernando D.} and Rukstalis, {Daniel B.}",
year = "2013",
month = "12",
doi = "10.1016/j.juro.2013.05.116",
language = "English (US)",
volume = "190",
pages = "2161--2167",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia

T2 - The L.I.F.T. study

AU - Roehrborn, Claus

AU - Gange, Steven N.

AU - Shore, Neal D.

AU - Giddens, Jonathan L.

AU - Bolton, Damien M.

AU - Cowan, Barrett E.

AU - Thomas Brown, B.

AU - McVary, Kevin T.

AU - Te, Alexis E.

AU - Gholami, Shahram S.

AU - Rashid, Prem

AU - Moseley, William G.

AU - Chin, Peter T.

AU - Dowling, William T.

AU - Freedman, Sheldon J.

AU - Incze, Peter F.

AU - Scott Coffield, K.

AU - Borges, Fernando D.

AU - Rukstalis, Daniel B.

PY - 2013/12

Y1 - 2013/12

N2 - Purpose: We report the first multicenter randomized blinded trial of the prostatic urethral lift for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Materials and Methods: Men at least 50 years old with AUASI (American Urological Association Symptom Index) 13 or greater, a maximum flow rate 12 ml per second or less and a prostate 30 to 80 cc were randomized 2:1 between prostatic urethral lift and sham. In the prostatic urethral lift group small permanent implants are placed within the prostate to retract encroaching lobes and open the prostatic urethra. Sham entailed rigid cystoscopy with sounds mimicking the prostatic urethral lift. The primary end point was comparison of AUASI reduction at 3 months. The prostatic urethral lift arm subjects were followed to 1 year and assessed for lower urinary tract symptoms, peak urinary flow rate, quality of life and sexual function. Results: A total of 206 men were randomized (prostatic urethral lift 140 vs sham 66). The prostatic urethral lift and sham AUASI was reduced by 11.1 ± 7.67 and 5.9 ± 7.66, respectively (p = 0.003), thus meeting the primary end point. Prostatic urethral lift subjects experienced AUASI reduction from 22.1 baseline to 18.0, 11.0 and 11.1 at 2 weeks, 3 months and 12 months, respectively, p <0.001. Peak urinary flow rate increased 4.4 ml per second at 3 months and was sustained at 4.0 ml per second at 12 months, p <0.001. Adverse events were typically mild and transient. There was no occurrence of de novo ejaculatory or erectile dysfunction. Conclusions: The prostatic urethral lift, reliably performed with the patient under local anesthesia, provides rapid and sustained improvement in symptoms and flow, while preserving sexual function.

AB - Purpose: We report the first multicenter randomized blinded trial of the prostatic urethral lift for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Materials and Methods: Men at least 50 years old with AUASI (American Urological Association Symptom Index) 13 or greater, a maximum flow rate 12 ml per second or less and a prostate 30 to 80 cc were randomized 2:1 between prostatic urethral lift and sham. In the prostatic urethral lift group small permanent implants are placed within the prostate to retract encroaching lobes and open the prostatic urethra. Sham entailed rigid cystoscopy with sounds mimicking the prostatic urethral lift. The primary end point was comparison of AUASI reduction at 3 months. The prostatic urethral lift arm subjects were followed to 1 year and assessed for lower urinary tract symptoms, peak urinary flow rate, quality of life and sexual function. Results: A total of 206 men were randomized (prostatic urethral lift 140 vs sham 66). The prostatic urethral lift and sham AUASI was reduced by 11.1 ± 7.67 and 5.9 ± 7.66, respectively (p = 0.003), thus meeting the primary end point. Prostatic urethral lift subjects experienced AUASI reduction from 22.1 baseline to 18.0, 11.0 and 11.1 at 2 weeks, 3 months and 12 months, respectively, p <0.001. Peak urinary flow rate increased 4.4 ml per second at 3 months and was sustained at 4.0 ml per second at 12 months, p <0.001. Adverse events were typically mild and transient. There was no occurrence of de novo ejaculatory or erectile dysfunction. Conclusions: The prostatic urethral lift, reliably performed with the patient under local anesthesia, provides rapid and sustained improvement in symptoms and flow, while preserving sexual function.

KW - Prostate

KW - Prostatic hyperplasia

KW - Surgical procedures, minimally invasive

KW - Therapeutics

KW - Urethra

UR - http://www.scopus.com/inward/record.url?scp=84888642558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888642558&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2013.05.116

DO - 10.1016/j.juro.2013.05.116

M3 - Article

C2 - 23764081

AN - SCOPUS:84888642558

VL - 190

SP - 2161

EP - 2167

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -